about
sameAs
Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndromePrimary and secondary autoimmune neutropenia.Correlation of the score for subjective pain with physical disability, clinical and radiographic scores in recent onset rheumatoid arthritisEffect of adalimumab on neutrophil function in patients with rheumatoid arthritisInfections and Biological Therapy in Patients with Rheumatic DiseasesDo Anti-TNF Blockers Increase the Risk of Lung Involvement in Patients with Ankylosing Spondylitis or Psoriatic Arthritis? A Systematic ReviewOne year in review 2016: fibromyalgiaImproving inflammatory arthritis management through tighter monitoring of patients and the use of innovative electronic toolsSkin manifestations in vasculitis and erythema nodosumDouble-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndromeEULAR revised recommendations for the management of fibromyalgia.High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: data from GISEA, the Italian biologics register.Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry.A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data.Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis.Morphological distribution of μ chains and cd15 receptors in colorectal polyp and adenocarcinoma specimensFactors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia.Influence of autonomic nervous system dysfunction in the genesis of sleep disorders in fibromyalgia patients.Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography.Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study.Central motor control failure in fibromyalgia: a surface electromyography study.From endothelial dysfunction to atherosclerosis.Doctors' insights into the patient perspective: a qualitative study in the field of chronic painB lymphocyte intestinal homing in inflammatory bowel disease.The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases.Clinical and laboratory aspects of Ro/SSA-52 autoantibodies.Pain and ketoprofen: what is its role in clinical practice?Overactive lifestyle in patients with fibromyalgia as a core feature of bipolar spectrum disorder.The management of chronic pain in important patient subgroups.Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis.Neurophysiological background for physical therapies in fibromyalgia.Osteoarthritis: an overview of the disease and its treatment strategies.Clinical implications of autoantibody screening in patients with autoimmune myositis.Vascular endothelial growth factor gene polymorphisms in Behçet's disease.Safety of rituximab in rheumatoid arthritis.Chronic widespread pain in the spectrum of rheumatological diseases.EULAR evidence-based recommendations for the management of fibromyalgia syndrome.Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.Is atherosclerosis an autoimmune disease?
P50
Q21195658-82447A79-E936-4C42-A8FF-F0B2649CFCB9Q24535985-2DAFC8E9-3C7B-4BFD-B705-509215FD1EF2Q24798428-6E891F65-33E2-471C-A98F-9E0CD5591CACQ24803670-A108D2CE-ABE1-4899-9318-0A0C929727F2Q26745743-55F07BE5-0C6C-4719-95BD-E3DBC2844288Q26745746-DC4AF0EA-0A11-46DE-8B89-05B4AF6608ADQ26751347-C65D5ABB-B21E-4F55-91B2-344E9E96F8BDQ28071252-D8B2A004-56EE-4FC8-BC89-0655FC63FDD1Q28194931-02CA5098-A9FC-4006-A2AF-DD11CF5730EAQ28331055-8510A8F6-2F44-42C8-B798-51271067970EQ30249155-F6D38117-47C4-4063-8802-7C71AF59B93BQ30662067-E5ECBEAF-296B-4C53-8221-9A98AEC216C0Q30841797-C1C6B947-0CB7-42B8-B213-2688CA034A93Q30912199-FB3CF176-E65D-4507-917C-EC15B122AE60Q31078960-0E23FCD6-651A-4F5B-BC58-FA1AABDD0384Q31111890-7D460D30-9F8A-45A8-89D7-7B4D8D2E0E4DQ31153194-05775FFD-A998-405E-84A8-1D20279C2E6BQ33153045-32853925-CCFE-4BD7-BFEA-4D49EBB33448Q33168851-A14875D4-3391-4DD4-B596-890CA1CCE0B4Q33334045-759695DE-53A3-4446-903C-EBE2D559BB1EQ33366716-961D9A53-6708-4F17-A583-91A27ED72206Q33477115-365BEC50-30DC-41AD-8B42-3BFC4AD92DE3Q33647535-5765F2ED-2D05-47E1-B154-EAEAB4CF0929Q33735822-DFC7156C-DC2E-4BA1-8BFD-830D58AEC202Q34114485-A1EF8325-72AD-4186-8E8C-C5D92B5C5262Q34129198-6E577155-FC4B-4436-BD0A-30A3DCD31BAEQ34138964-E1FC4A99-D715-46C0-98E8-8CBCBF047ED5Q34148266-62BEACFE-2580-4E67-8FC2-2015F811C9D3Q34319100-3E595846-897F-4FB0-908E-78597A75FD4BQ34326675-694137AE-82D5-4051-959E-1FB7A7C0E712Q34347034-EEFC3FDF-B713-43B8-A4B9-2B9CEA0EB245Q34425413-FED89E23-DE2D-4DEE-8AFE-07F0FA7F5C3EQ34440851-99DD7F3F-0B01-401F-BBB2-EAD1F679946BQ34537296-88D28D6B-6D74-4DEB-B77C-62C26187F589Q34550545-71D800F5-D915-47AE-8731-289919834B25Q34621868-E22FAC7D-E37D-4D05-9128-0ADA464FDC33Q34633771-DE150209-D28F-452D-A427-0054372DD933Q34654765-798D7910-B52C-4205-8716-627C7FDDC462Q34896439-0E166953-64E0-45BD-80A2-6DCB65F9CD06Q35123740-9859994A-542B-4768-A901-D9DDE5622941
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Piercarlo Sarzi-Puttini
@an
Piercarlo Sarzi-Puttini
@ast
Piercarlo Sarzi-Puttini
@br
Piercarlo Sarzi-Puttini
@ca
Piercarlo Sarzi-Puttini
@co
Piercarlo Sarzi-Puttini
@da
Piercarlo Sarzi-Puttini
@de
Piercarlo Sarzi-Puttini
@en
Piercarlo Sarzi-Puttini
@es
Piercarlo Sarzi-Puttini
@eu
type
label
Piercarlo Sarzi-Puttini
@an
Piercarlo Sarzi-Puttini
@ast
Piercarlo Sarzi-Puttini
@br
Piercarlo Sarzi-Puttini
@ca
Piercarlo Sarzi-Puttini
@co
Piercarlo Sarzi-Puttini
@da
Piercarlo Sarzi-Puttini
@de
Piercarlo Sarzi-Puttini
@en
Piercarlo Sarzi-Puttini
@es
Piercarlo Sarzi-Puttini
@eu
prefLabel
Piercarlo Sarzi-Puttini
@an
Piercarlo Sarzi-Puttini
@ast
Piercarlo Sarzi-Puttini
@br
Piercarlo Sarzi-Puttini
@ca
Piercarlo Sarzi-Puttini
@co
Piercarlo Sarzi-Puttini
@da
Piercarlo Sarzi-Puttini
@de
Piercarlo Sarzi-Puttini
@en
Piercarlo Sarzi-Puttini
@es
Piercarlo Sarzi-Puttini
@eu
P214
P244
P1053
S-6457-2017
P106
P1153
35477093200
P21
P214
P244
n2005184631
P31
P3829
P496
0000-0002-8673-5133
P735
P7859
lccn-n2005184631